Investment Summary

PetMedix is applying 30 years of antibody research to develop new pet therapeutics against a wide range of diseases.

Antibody therapeutics have been transformative in human medicine, treating a wide range of diseases including cancers, autoimmune diseases, and inflammatory conditions. The companion animal therapeutics market represents a $14bn opportunity, and one that is already embracing the promise of veterinary biologics. There are currently only a few veterinary biologic products on the market, but regulators, purchasing groups, insurers, veterinarians, and owners have all been highly receptive to them, and demand continues to grow.

PetMedix intends to realise this potential for veterinary medicine and give veterinarians, owners, and our pets the therapies they need to treat the conditions causing the most harm.

PetMedix is built from the same world-leading transgenic technology that underpins the most successful and advanced human antibody platforms available today. From platform development through drug discovery, PetMedix is dedicated to applying the very latest technology to deliver the best antibody-based drug therapies possible.